HK1139161A1 - Prevention and treatment of complement- associated eye conditions - Google Patents

Prevention and treatment of complement- associated eye conditions

Info

Publication number
HK1139161A1
HK1139161A1 HK10105890.8A HK10105890A HK1139161A1 HK 1139161 A1 HK1139161 A1 HK 1139161A1 HK 10105890 A HK10105890 A HK 10105890A HK 1139161 A1 HK1139161 A1 HK 1139161A1
Authority
HK
Hong Kong
Prior art keywords
complement
prevention
treatment
eye conditions
associated eye
Prior art date
Application number
HK10105890.8A
Other languages
English (en)
Chinese (zh)
Inventor
Philip Hass
Yin Jianping
Kenneth Katschke Jr
Micah Steffek
Christian Wiesmann
Campagne Menno Van Lookeren
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1139161(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1139161A1 publication Critical patent/HK1139161A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
HK10105890.8A 2007-05-23 2010-06-13 Prevention and treatment of complement- associated eye conditions HK1139161A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (1)

Publication Number Publication Date
HK1139161A1 true HK1139161A1 (en) 2010-09-10

Family

ID=39638868

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10105890.8A HK1139161A1 (en) 2007-05-23 2010-06-13 Prevention and treatment of complement- associated eye conditions
HK15107851.6A HK1207327A1 (en) 2007-05-23 2015-08-14 Prevention and treatment of complement-associated eye conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15107851.6A HK1207327A1 (en) 2007-05-23 2015-08-14 Prevention and treatment of complement-associated eye conditions

Country Status (28)

Country Link
US (6) US8007791B2 (xx)
EP (1) EP2152755B1 (xx)
JP (4) JP5416695B2 (xx)
KR (1) KR101540126B1 (xx)
CN (3) CN101754980B (xx)
AR (1) AR066660A1 (xx)
AU (1) AU2008256835B2 (xx)
BR (1) BRPI0811142A8 (xx)
CA (1) CA2683498A1 (xx)
CL (1) CL2008001498A1 (xx)
CY (1) CY1116062T1 (xx)
DK (1) DK2152755T3 (xx)
ES (1) ES2533242T3 (xx)
HK (2) HK1139161A1 (xx)
HR (1) HRP20150281T1 (xx)
IL (2) IL201476A (xx)
MX (1) MX2009012422A (xx)
PE (1) PE20090294A1 (xx)
PH (1) PH12013500992B1 (xx)
PL (1) PL2152755T3 (xx)
PT (1) PT2152755E (xx)
RS (1) RS53901B1 (xx)
RU (2) RU2522976C2 (xx)
SG (1) SG10201401404RA (xx)
SI (1) SI2152755T1 (xx)
TW (2) TWI419704B (xx)
WO (1) WO2008147883A1 (xx)
ZA (1) ZA200907028B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
SI2907827T1 (sl) 2006-11-02 2019-02-28 Genentech, Inc. Humanizirana protitelesa proti faktorju D in njihova uporaba
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CA2735779A1 (en) * 2008-09-02 2010-03-11 Matthew Burger Bicyclic kinase inhibitors
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
CA2807554C (en) * 2010-08-05 2021-10-26 Forsight Vision4 Inc. Implantable therapeutic device
NZ610067A (en) * 2010-11-01 2015-05-29 Genentech Inc Predicting progression to advanced age-related macular degeneration using a polygenic score
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
CN105121429B (zh) 2012-06-28 2017-12-12 诺华股份有限公司 补体途径调节剂和其用途
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
US20160339008A1 (en) * 2013-10-25 2016-11-24 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
KR20160147855A (ko) * 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
WO2017053753A1 (en) * 2015-09-23 2017-03-30 Sangamo Biosciences, Inc. Htt repressors and uses thereof
RS61871B1 (sr) 2015-10-30 2021-06-30 Hoffmann La Roche Anti-htra1 antitela i postupci za njihovu primenu
CA3002671A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Methods of measuring factor d activity and potency of factor d inhibitors
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN108699121B (zh) 2015-12-23 2023-07-04 艾丽法有限责任公司 用于抑制补体激活的多肽
WO2017127761A1 (en) * 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
IL268601B1 (en) * 2017-02-10 2024-03-01 Univ Pennsylvania Antibodies against factor D and their uses
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009777A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods of stem cell culture for obtaining products, and implementations thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001036432A2 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69840105D1 (de) 1997-11-21 2008-11-20 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1054693B8 (en) 1998-02-20 2009-03-04 Genentech, Inc. Inhibitors of complement activation
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
JP2002523089A (ja) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド タンパク質輸送関連分子
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000037025A2 (en) * 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
KR100499600B1 (ko) 1998-12-22 2005-07-07 제넨테크, 인크. 신생 세포 성장을 억제하기 위한 방법 및 조성물
NZ514091A (en) 1999-03-11 2004-01-30 Rmf Dictagene S Vascular adhesion molecules and modulation of their function
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
CA2492070A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
UA99591C2 (ru) * 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
SI2907827T1 (sl) * 2006-11-02 2019-02-28 Genentech, Inc. Humanizirana protitelesa proti faktorju D in njihova uporaba
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
EP2152755B1 (en) 2014-12-31
AU2008256835A1 (en) 2008-12-04
RU2009147744A (ru) 2011-06-27
AR066660A1 (es) 2009-09-02
US8268310B2 (en) 2012-09-18
IL201476A0 (en) 2010-05-31
CY1116062T1 (el) 2017-02-08
JP2016145205A (ja) 2016-08-12
RU2014113046A (ru) 2015-10-10
CN101754980A (zh) 2010-06-23
PT2152755E (pt) 2015-04-01
US8007791B2 (en) 2011-08-30
PL2152755T3 (pl) 2015-06-30
JP2014087346A (ja) 2014-05-15
JP5416695B2 (ja) 2014-02-12
MX2009012422A (es) 2009-12-04
EP2152755A1 (en) 2010-02-17
JP2017197577A (ja) 2017-11-02
IL248552A0 (en) 2016-12-29
ZA200907028B (en) 2010-12-29
CN107096029A (zh) 2017-08-29
SG10201401404RA (en) 2014-08-28
IL201476A (en) 2016-11-30
KR20100033973A (ko) 2010-03-31
JP2010528047A (ja) 2010-08-19
TWI419704B (zh) 2013-12-21
US20130302333A1 (en) 2013-11-14
CL2008001498A1 (es) 2009-06-12
TW201417829A (zh) 2014-05-16
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
RS53901B1 (en) 2015-08-31
WO2008147883A1 (en) 2008-12-04
CN107096029B (zh) 2021-02-26
KR101540126B1 (ko) 2015-07-28
ES2533242T3 (es) 2015-04-08
US20130052685A1 (en) 2013-02-28
CA2683498A1 (en) 2008-12-04
PE20090294A1 (es) 2009-03-27
US20160272726A1 (en) 2016-09-22
SI2152755T1 (sl) 2015-05-29
CN101754980B (zh) 2014-10-29
US20110282034A1 (en) 2011-11-17
US20180079826A1 (en) 2018-03-22
TW200904471A (en) 2009-02-01
RU2522976C2 (ru) 2014-07-20
WO2008147883A8 (en) 2013-05-23
HRP20150281T1 (hr) 2015-04-10
PH12013500992A1 (en) 2016-01-25
US8497094B2 (en) 2013-07-30
DK2152755T3 (en) 2015-03-02
US20090181017A1 (en) 2009-07-16
HK1207327A1 (en) 2016-01-29
BRPI0811142A8 (pt) 2018-12-18
PH12013500992B1 (en) 2016-01-25
CN104367999A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
IL248552A0 (en) Prevention and treatment of related eye conditions - complementary
PL2583978T3 (pl) Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
ZA200904806B (en) Prevention and treatment of sub-clinical pcvd
ZA201105287B (en) Prevention and treatment of rotavirus diarrhoea
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
ZA200907209B (en) Prevention and treatment of cerebral amyloid angiopathy
ZA200905101B (en) Diagosis and treatment of preeclampsia
ZA200908100B (en) Treatment and prevention of influenza
GB0705488D0 (en) Treatment of inflammation and/or endotoxic shock
HK1184169A1 (zh) 共核蛋白病和致澱粉樣病的預防和治療
HK1130434A1 (en) Treatment and prevention of excessive scarring
EP2274042A4 (en) TREATMENT AND / OR PREVENTION OF MULTIPLE SCLEROSIS
AP3019A (en) Use of ferroquine in the treatment or prevention of malaria
EP2331135A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF GLUCOSE TOXICITY
HU0800012D0 (en) Novel use and methods for the treatment and prevention of ulcerative colitis
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases
GB0811950D0 (en) Disease prevention and treatment
EP2276502A4 (en) COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROLOGICAL INJURIES AND ASSOCIATED METHODS OF USE
GB0612749D0 (en) Treatment and/or prevention of pain
AU2007902616A0 (en) Treatment and prevention of influenza
TWI367093B (en) Hydroxy-morusin-treatment and/or prevention of mouth diseases
GB0619506D0 (en) Increasing of intelligence and or treatment of mental retardation
GB0716577D0 (en) Treatment and prevention of neurodegenerative diseases
GB0803515D0 (en) Medicament and method of treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220520